BioMarin Pharmaceutical Inc. Stock Soars on Positive Drug Data
Treatment with GALNS Significantly Improves Primary Endpoint
The primary endpoint of the study, change in six-minute walk distance at 24 weeks, was statistically significant in patients dosed with GALNS at 2 mg/kg every week with a mean increase of 22.5 meters (p=0.0174) over placebo. In MOR-004, patients dosed at 2 mg/kg every week showed an improvement in six-minute walk distance at week 12 compared to baseline and showed continued improvement at week 24. Preliminary analysis of a subset of the patients in the MOR-005 extension study who have reached the 36 week and 48 week timepoints in the study also showed further improvement at weeks 36 and 48.
Treatment with GALNS Improves Both Secondary Endpoints
On the secondary endpoint of three-minute stair climb, patients dosed with GALNS at 2 mg/kg every week showed a trend toward improvement at 24 weeks of 1.1 additional stairs per minute over placebo. In MOR-004, patients dosed with GALNS at 2 mg/kg every week showed an improvement in three-minute stair climb performance at week 12 compared to baseline and showed continued improvement at week 24. Preliminary analysis of a subset of patients in the extension study (MOR-005) who have reached the 36 week and 48 week timepoints in the study also showed further improvement in three-minute stair climb performance.
In the other secondary endpoint, urinary keratan sulfate (KS) levels, patients dosed with GALNS at 2 mg/kg every week showed consistent and robust reduction in urinary KS with a mean difference from baseline as compared to placebo of 40.7 percent (p less than 0.0001). Preliminary analysis of a subset of patients in the extension study (MOR-005) who have reached the 36 week and 48 week timepoints in the study showed this level of reduction was maintained.
Treatment with GALNS Improves Pulmonary Function
Pulmonary function, as defined by maximum voluntary ventilation (MVV) was measured at 24 weeks. In MOR-004, patients dosed with GALNS at 2 mg/kg every week showed a trend toward improvement from baseline of 10.3 percent over placebo. Preliminary analysis of the subset of patients who reached the 48 week timepoint showed a reduction in the improvement, though an increase over baseline was maintained.
Pulmonary function, as defined by forced vital capacity (FVC) was measured at 24 weeks. In MOR-004, patients dosed with GALNS at 2 mg/kg every week showed a trend toward improvement from baseline of 3.3 percent over placebo. Preliminary analysis of the subset of patients who reached the 48 week timepoint showed continued improvement.